OncLive® On Air S13 Ep38: Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD
Aug 4, 2025
In this discussion, Dr. Martin F. Dietrich, a medical oncologist and assistant professor, dives into the significance of HER2 and MET immunohistochemistry testing for non-small cell lung cancer patients. He outlines the rationale for testing and the challenges oncologists face in implementing these guidelines. The conversation highlights the importance of retesting as patients progress, the potential of novel therapies, and the need for standardized workflows to improve patient outcomes in oncology.
AI Snips
Chapters
Transcript
Episode notes
Order Comprehensive Profiling Upfront
- Order comprehensive molecular profiling (NGS) plus PD-L1 and add HER2 and MET IHC at diagnosis.
- Keep these results available to guide rapid, biomarker‑driven second-line care.
Use 3+ And ≥50% Cutoffs For Actionability
- Regard only 3+ strong surface expression as actionable for HER2 and MET IHC.
- For MET actionability, require ≥50% of tumor cells positive before discussing targeted ADC therapy.
Prioritize Drivers First, Save IHC For Progression
- Prioritize actionable driver mutations for first-line targeted therapy and immunotherapy decisions.
- Preserve HER2 and MET IHC results for second-line planning rather than acting on them up front.